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Effectivenessofan AggrsseiveLipidLowering
Stretegyto PreventSVGAtherosclerosis:Results
fromthe NHLBIPostCABGTrial
C.W. White, L. Campeau, M. Domanski, J. Forrester, N. Geller, F.Gobel,
J.A. Herd, B. Hoogwerf, D. Hunninghake, G. Knatterud, Y. Rosenberg,
Z. Rozsa for the Post-CABG investigatora. Urriveraifyof A4irrnesota,
Minneapolis, MN, USA
The PostCABG Clinical Trial, a quantitative angiographic study of 1351
patients who underwent SVG surgery 1 to 11 years previously, has re-
eently shown that an aggressive lipid lowering strategy (mean low density
lipoprotein-cholesterol (LDL-C)93m@dl), Censignifieentlyreduceatheroscle-
rotic obstructive changes in SVGScompared to a moderate strategy (mean
LDL-D 136 mg/dl), after a mean of 4.5 years of therapy. The aim of this
analysis was to assess whether the efficacy of lipid lowering therapy in re-
ducing the probability of significant worsening (Prob. SW) is influenced by
grsft age (time of surgery to atudy enrollment when therapy was initiated.)
Signifieent worsening was defined as a >0.6 mm decrease in the minimum
Ieaion diameter (D) of preexisting lesions (>15% D stenosis on the initial
angiogram) for each graft.
LDL-CLowerirw n Aggressive n Moderate p
CMtAge (yr) - P;ib, SW Prob.SW
1-4 544 16,7 530 23.2 0.026
>4-6 614 33.6 566 48.2 <00001
>8 202 39.6 222 55.0 00062
The interaction between treatment effect and graft agesubcetegories was
not significant (p= 0.33). Similar treatment effects were seen after adjusting
for other baseline variablea, or when aaseaeing new lesion development in
SVGSwithout prior etenoees.
Cone/uaion:SVGatheroeclarosis womens with increasing graft age. How-
ever, an aggressive lipid lowering strategy een significantly reduce the prob-
ability of SVG diaeaee regardless of the time of initiation of lipid-lowering
therapy.
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El8062 DifferencesinLipidMensgementAcrosetheSpectrumof AcuteCoronsryArteryDisesse
R.P. Giugliano, C.A. Camargo, Jr., O.M. Lloyd-Jonee, R.C. Pasternak,
C.J. O’Donnell. f-/arvardMedica/School, Boston, MA, USA
Background: Recent trial results support earfy identification and treatment
of even mild lipid abnormalities in patients with unstable angina (ua), non-
ST-elevation Ml (nSTE-Ml), and ST-elevation Ml (STE-MI). It ia not known,
however, whether there ie significant variation in the prevalence of hyperc-
holesterolemia (HC), lipid testing, or HC management across the spectrum
of acute coronary artery disease. Methods: We identified 385 eonsaeutive
nonreferral petiante (median age 65, 89% male) with acute coronaty artery
disease admitted directly from the emergency department to an intensive
care or telemetry unit of an urban academic hospital in 1992. HC was de-
fined aa a total cholesterol (TC) >240 m~dl or therapy with a lipid lowering
drug. Resufts: There were significant differences in pre-admission (pre) and
discharge (DC) date across the speetrum of acute coronary artery disease,
including unknown TC and lipid lowering drug at diacharge (both p = 0.001).
UA (n = 213) nSTE-Ml (n=67) STE-MI (n= 105)
pre Dc pre DC pre DC
UnknownTC 28% 10% 34% 26% 47% 2s%
HC notpresent 204A 33% 15% 23% 174A 30%
HC present 53% 57% 51% 51% 360,4 41%
Drug therapy 23% 21% 19% 20% 7% 6“/0
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S. O’Mahoney, P.G.Danias, D.1.Silverman, L. Korman, M.J. Radford.
University of Connecticut Health Centac Farmington CT USA, Connecticut
V.A.Health Care System, Newington Campus, Newington CT USA
Although the importance of aggressive treatment of elevated cholesterol
levels (TC) has been documented for both primary and secondary prevention
of coronary artey disease (CAD), current physician (MD) practice regarding
management of high TC has not been adequately studied. Accordingly,
we evaluated 147 serial patients (pts) routinely followed at a teaching VA
hospital, with TC levels obtained from 10/1/94 to 1.2/31/94.We analyzed MD
response to TC values over the next 12 months. Out of 44 pts (30%) with
clinical CAD, only 20 (45%) had a complete lipid profile. Of theee, 13 pta
(65%) had LDL ? 130 mg/dl, and only 8 (82%) were prescribed lipid lowering
agents. Of the 103 remaining pts without CAD, 64 (8W.) had 22 coronary
risk factors (CRFS).Of these pts, 39 (48%) had lipoprotein analysis and from
these 11 (28%) had LDL ? 180 mg/dl. Only 3 pts (27%) from this subset
were prescribed lipid lowering agents. From our series, a total of 25 pts met
NCEP criteria for medical treatment of high LDL levels (13 with CAD and
LDL z 130 m@dl, 11 with 22 CRFS and LDL ? 160 mg/dl and one with <2
CRFsand LDL ? 190 mg/dl), and of these only 11pts (44%) were prescribed
lipid lowering agents. Within 1 year of follow-up, only 14 pts had repeat LDL
checked and of these only 5 (38%) had achieved a 20% reduction in the initial
LDL level. Conclusion: Despite extensive epread of information regarding the
importance of TC management and published practice guidelines, pts with
high TC remain largely underevaluatad and undertreated. Our data strongly
suggest the need for more extensive MD awareness and education regarding
the appropriate management of hypercholesterolemia.
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S.R. Weissl, R. Knopp2, M. Davidson3, E.A. Stein4, P. Leskerzewski4,
DR. lllingwotth5, C. Dujovne6, D. Hunninghake7, M.R. Melino8,
Y.B. Mitchele. 1San Diego, CA, USA, 2Seattle, WA, USA, 3 Chicago, IL,
USA, 4 Cincinnati, OH, USA, 5 Porfland, OR, USA, 6Kansas CiM MO, USA,
7Minneapolis, MN, USA, 8Merck Research Labs, RahwaK NJ, USA
To reach the NCEP target LDL cholesterol (C) level of cICSJ mgldl, pe-
tients with CHD and hypercholesterolemia often require LDL-C reductions
greater than the 40% achieved with the maximum dose of available drugs.
To evaluate the efficacy and safety of aimvastatin at doses above the current
maximum dose of 40 mg/d, 156 subjects with an LDL-C > 180 m~dl and
triglycerides (TG) <350 mg/dl were randomized to aimvastatin at doses of
40, 80 and 160 mg hs in a 28 week, double-blind, three period, complete
block cross-overstudy. Each active treatment period wae 6weeks in duration
with intervening 2 week washout periods. Median Y. change from baseline
(BL) in lipids and lipoproteins were:
BL (mg/dl) 40 mg.ld SOmgld 160 mgrd
n 140 144 141
T Chol 2s2 -30 -35 -40
LDL-C 199 -41 -47 -53
TG 179 -21 -23 -33
HDL 47 9 9 10
No new or unexpected clinical adverse events were obaerved. With the
160 mg doae, 1 patient (0.7%) had muscle pain and a creatine kinase
elevation >10 times the upper limit of normal (ULN) and 2 (1.4%) had ALT
increaaes >3 times the ULN. On the 80 mg dose, 1 patient (0.7%) had an
increase in ALT >3 times the ULN.
Surnrnary:Higher doses of simvastatin provide additional LDL-C and TG
lowering. Their safety and tolerability need to be evaluated in larger triala of
longer duration.
Conckmiona: (1) TC was unknown at discharge in >25% of patients with
Ml. (2) Deepite a substantial prevalence of HC (at least 41%), only 6% of
patients with STE-MI reeeived lipid lowering drug therapy at diaeharge. (3)
Given results of recent trials, these data support increasad attention to early
identification of HC and the importance of lipid management in patients with
acute coronary artery disease.
